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T he different starting points and uneven empha-
sis of historical accounts of transplantation l 
have tended to obscure the contributions to this field 
of some of the grand figures of French medicine and 
science. Clinical transplantation activity began in 
France within the first few years of the 20th century, 
when Jaboulay in Lyon2 and other investigators in 
France and Germany performed subhuman primate 
to human kidney heterotransplantationY; In 1936, 
the Russian Yu Yu Voronoy of Kiev made the first 
known attempt at renal allotransplantation.6 
The field of transplantation lay largely dormant 
until 1951 when Rene Kussl and Charles DubostG of 
Paris and Marceau Servelle of Strasbourg9 per-
formed a series of cadaveric renal transplantations. 
The kidneys were removed from comict donors after 
their execution by guillotine. The next year, French 
physician Jean Hamburger, working with urologist 
Louis Michon at the Hopital Necker (Paris) reported 
the now commonplace transplantation of a kidney 
from a live volunteer donor. 1O The pelvic kidney 
transplant procedure originally used by Kuss and 
refined subsequently by the French surgeons has 
been used hundreds of thousands of times since then 
including for the celebrated identical (monozygotic) 
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twin transplantations performed by Murray (Nobel 
laureate 1990) and his associatesll in Boston. 
Visitors flocked to France in the early 1950s to 
learn first hand from this experience, including John 
Merrill of Boston, as Hume described in the classical 
account of his own clinical trials at the Peter Bent 
Brigham Hospital. 12 The extensive discussion of the 
French experience by Hume was typical of this man 
whose awareness and acknowledgment of other peo-
ple's work was noteworthy throughout his illustrious 
career. As important as these and later contributions 
ofKuss ll and Hamburger l4 were, the scientific basis 
for transplantation in France went far deeper. The 
roots of histocompatibility research were nourished 
in France by Jean Dausset (Nobel Laureate 1980),15 
In addition, George i\Iathe, the father of cell trans-
plantation, was part of the Paris clique of the 1950s 
and early 1960s. 
The skills necessary to transplant the kidney (the 
only candidate organ until the 1960s) were applica-
tions of what were becoming conventional surgical 
practices after World War II, The vascular surgical 
technology came from the Frenchman Alexis Car-
reljI(i and had a pervasive effect on essentially all 
surgical specialties, Although Carrell understood 
that transplanted organs were not permanently ac-
cepted, the biological specificity of the field of trans-
plantation was defined by Medawar when he showed 
that rejection is an immunologic evenL l7,IH In retro-
spect, every further development was a logical and 
inevitable step from this beginning. If rejection was 
in fact an immune reaction, what could be more 
logical than to protect the organ transplant by 
weakening the immune system? Medawar's conclu-
sion about the nature of rejection was strengthened 
when it was shown more than 40 years ago that 
adrenal corticosteroids19,20 and total body irradia-
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tion/ I which already were known to diminish immu-
nologic responses, significantly prolonged skin graft 
sun'ival. 
The relatively modest delay of rejection of rodent 
skin grafts made possible with corticosteroids and 
total body irradiation was not an open imitation for 
clinical application.l\"or was there a clinical mandatc 
in the 1953 articlc by Billingham et aj22 that de-
scribed permanent skin graft acceptance in a special 
circumstance not invoh'ing iatrogenic immunosup-
pression. The unique circumstance was the inocula-
tion of fetal or perinatal mice ,dth immunocompe-
tent spleen cells. Instead of being rejected, these cclls 
survived and endowed the recipient with the ability in 
later life to accept other allogeneic tissues (in their 
experiments skin) from the original donor strain.22 ,2) 
As Billingham, Brent, and Medawar (later re-
ferred to as the "holy trinity") meticulously anno-
tatcd, the impetus and rationale for these experi-
ments came originally from the observation by Owen24 
that freemartin cattle (the calf equivalents of human 
fraternal t\\ins) were permanent hematopoietic chi-
meras if placental fusion and fetal cross-circulation 
had existed in utero. Burnet and Fenner25 predicted 
that such chimerism and thc ability to exchange 
other tissues could be induced by the kind of experi-
ment eventually performed with Medawar by Billing-
ham and Brent whosc definition of tolerance was 
that it "is due to a primary central failure of the 
mechanism of the immunological reaction, and not 
to some intercession, at a peripherallevel."23 
The surgical interest generated by thc dcmonstra-
tion that tolerance could be acquired was quickly 
dampened whcn it was learned by Billingham and 
Brent26 with further experiments in mice that the 
penalty for the prophylactic infusion of such donor 
cells could be lethal graft-versus-host disease 
(GVHD). Many of the inoculated mice failed to 
thrive ("runt disease") and had skin erosions, hair 
loss, diarrhea, diffuse pneumonitis, and characteris-
tic changes in their lymphoid organs. Donor immune 
cells were found everywhere in the recipient tissues. 
The objective of producing specific and stable 
allogeneic (often called ~fedawarianF nonresponsive-
ness became the holy grail of transplantation when in 
1955, Main and Prehn27 simulated in adult mice an 
environment lhat they likened to that in perinatal 
Billingham-Brent-Medawar animals. The three steps 
were first, to cripplc the immune system with supra-
lethal total body irradiation, ncxt to rescue it with 
allogeneic bone marrow (creating a chimera), and 
finally to engraft skin from the bone marrow donor. 
Their efforts were successful. vVhen the results of 
Main and Prehn were confirmed by Trentin,2B the 
prototype strategy for induction of tolerance in large 
animals and in humans seemed at first to be obvious. 
Bad news was close behind. Within a few months, it 
became clear that GVHD similar to that in the 
perinatal mouse model could be expected almost 
invariably after all bone marrow engraftments that 
"took" following irradiation, except thosc from per-
fectly histocompatible donors. 
Although the bubble had burst, Mannick, Lochte, 
Ashley, Thomas, and Fcrrebee at Cooperstown, l\"'Y 
(an affiliate of Columbia University), produced bone 
marrow chimerism in 1958 in an irradiated beagle 
dog, followed by successful kidney allotransplanta-
tion from the original marrow donor. 29 The animal 
lived for 73 days before dying from pneumonitis and 
was the first "successful" marrow-kidney chimera in 
a large animal. However, efforts by Humc et apo and 
others to extend the Main-Prehn irradiation plus 
bone marrow technology to mongrel dog kidney 
transplantat ion was totally unsuccessfullv. Later, in 
summarizing his many years of collaborative re-
search with the Cooperstown group, Rapaport con-
firmed that this strategy could not work in dogs 
unless perfectly tissue-matched marrow donors were 
used-usually litter mates.3! Under all other condi-
tions, lethal GVHD, rejcction, or both were to be 
expccted. Appreciation of this dilemma by the clini-
cians caused a break in ranks in the late 1950s 
between those interested in bone marrow transplan-
tation for the treatment of hematologic disordcrs 
and those to whom the bone marrow was only the 
means to the end of transplantation of a needed solid 
organ of which the kidney was the sole candidate at 
the time. 
From this point onward, the therapeutic philoso-
phies of bone marrow and solid organ transplanta-
tion took separate pathways--one dependent and 
the other seemingly independent of classical toler-
ancc induction. In spitc of the consequent donor pool 
limitations (essentially only perfectly matched sib-
lings being permissible), bonc marrow transplanta-
tion, which was first accomplished clinically in 1968 
by Robert Good of the Univcrsity of Minnesota32 and 
soon thereafter by Thomas (Nobel Laureate 1990)33 
and yan Bekkum,34 matured into accepted clinical 
therapy for hematologic diseases and an assortment 
of other indications. 
In contrast, solid organ transplant surgeons were 
quick to abandon effort to produce specific allogeneic 
unresponsiveness with bone marrow. In Boston, Mur-
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ray and Merrill35 used the Main-Prehn principle of 
recipient preparation in their first two attempts at 
human kidney allotransplantation in 1958, but elimi-
nated the bone marrow component for the next 10 
recipients, using sublethal total body irradiation 
alone.35,36 Although 11 of their 12 irradiated recipi-
ents died after 0 to 28 days, the survivor, the recipient 
of a fraternal twin kidney inJ anuary 1959, lived until 
1979 and was the first example of a successful 
transplantation beyond the identical twin.35.37 
Five months later, Hamburger et aI'4,38,39 added a 
second successful fraternal (dizygotic) twin case. This 
patient had good renal function until his death 26 
years later from carcinoma of the urinary bladder. 
However, in the Boston and Paris fraternal twin 
recipients, the possibility remained that their individ-
ual placentas had cross-circulated with those of their 
kidney donors, like the conditions in Owen's freemar-
tin cattle. This possibility was precluded in the 
further extraordinary kidney transplant experience 
in France during 1960 and 1961 using total body 
irradiation without bone marrow reconstitution. 
Hamburger et al 14,39 succeeded with kidney transplan-
tation from a sibling and a first cousin. The cousin 
kidney functioned for 18 years before retransplanta-
tion was performed without interim dialysis in a 
patient who now is a member of the French parlia-
ment and the longest surviving kidney allograft 
recipient (32 years) from that heroic and primitive 
era.4() 
Also in Paris, Rene Kuss had long-term survival of 
three of six irradiated patients treated with kidney 
transplantation fromJ anuary 1960 through 1961.13,41 
This was a truly extraordinary achievement because 
two of Kuss's long surviving patients were given 
nonrelated kidneys (the first in June 1960) that 
functioned for 17 and 18 months. During the critical 
period of 1959 through early 1962, the cumulative 
French experience was the principal (and perhaps 
the only) justification to continue clinical kidney 
transplantation trials.42 By showing that bone mar-
row infusion was not a necessary condition for substan-
tial prolongation of kidney grafts, the stage was set 
for the transition to drug therapy. In fact, Kuss was 
using 6-mercaptopurine and steroids as adjuvant 
therapy in his patients as early as 1960.13 
Those examining this period historically have 
been inclined to consider irradiation-induced and 
drug-induced graft acceptance as different phenome-
na.4,36,37 However, it seems certain that the Boston 
and Paris fraternal twin kidney recipients, as well as 
the five long-surviving nontwin French recipients, 
had achieved to variable degrees the kind of graft 
acceptance that later was seen in tens of thousands of 
drug-treated humans after all kinds of whole organ 
transplantation. The fact that the mechanism was 
the same has been appreciated only in the last few 
months when it was realized that extensive migra-
tion and repopulation of sessile tissue leukocytes 
(most obviously of dendritic cells) from graft to host 
and vice versa are events common to the "acceptance" 
of all solid organs using any immunosuppressive 
modality-creating chimerism in the graft but also 
systemically in the recipient.43 \'\!hat has been achieved 
with drugs and antilymphoid agents compared with 
sublethal irradiation is a greater ease and reliability 
of achieving this transition. 
In view of the historic developments through 
1960, it was not surprising that the search for 
immunosuppressive drugs was focused at first on 
myelotoxic agents that were viewed as "space mak-
ers" for new donor or recovering recipient bone 
marrow, and thus the pharmacologic equivalent of 
total body irradiation. Willard Goodwin of Los Ange-
les achieved sublethal bone marrow "burn out" with 
methotrexate and cyclosphamide in a living related-
kidney recipient in September 1960, who subse-
quently developed rejection that was reversed with 
prednisone. This was the first example of protracted 
human kidney graft survival (143 days) with drug 
treatment alone.44 
Kidney transplant surgeons were quick to appreci-
ate that myelotoxicity should be avoided, not deliber-
atey imposed. The most important step in this 
evolution was the discovery by Schwartz and Dame-
schek that 6-mercaptopurine was immunosuppres-
sive without bone marrow depression in nontrans-
plant models.45 Within a few months, Schwartz and 
Dameschek46 and Meeker (working with Good)47 
showed that this drug could mitigate skin graft 
rejection in rats. Close behind, Calne48 and Zukos-
ki49 demonstrated independently of each other that 
kidney rejection in dogs also was ameliorated. 
\'\!hat was achieved in the earliest kidney trans-
plant experiments using drugs was delay of the 
inevitable rejection or else death of the animal from 
over immunosuppression. However, occasional exam-
ples of long-term or seemingly permanent allograft 
acceptance were observed throughout 1962 and 
19635()'53--defined as long survival of transplanted 
mongrel kidneys after a 4- to l2-month course of 
6-mercaptopurine or azathioprine was stopped. Since 
then, each new major immunosuppressive agent (or 
drug cocktail regimen), including cyclosporine and 
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FK506, has generated excited claims of the same 
phenomenon. Throughout the years, the most po-
tent agcnts for induction of this state have been the 
antilymphoid sera and globulins that at the begin-
ning were polyclonal agents54,55-but later highly 
specific monoclonal preparations.56 Although vari-
able in its incidence, the graft acccptance observed 
with all these modalities was indistinguishable and 
thus was not a treatment-specific phenomenon. 
This new kind of graft acceptance in outbred dogs 
was easier to produce with drugs than with total body 
irradiation, but the number of absolute examples 
was (and is) cxtremely small in contrast to what can 
be achieved todav in small rodents. In summarizing 
his research v~ith Caine, Alexandre, Sheil, and other 
investigators using azathioprinc,") Murray described 
a 20-day mortality of approximately 50% and a 
3-mon th mortality of 90% in a series of 120 mongrel 
dogs given daily treatment. Eventually a handful of 
long-survi\ ing animals « 5%) was the distillation 
from I ,000 experiments with 6-mercaptopurine or 
azathioprine performed in Boston by .\1urray's team 
in work that was initiated with the arrival there of Sir 
Roy Caine inJune 1960:)2 
The animals proudly displayed as chronic survi-
vors in laboratories of Boston, Denver, Richmond, 
and Minneapolis were those precious few who had 
run the gauntlet of therapy to the point where 
treatment was stopped. Our results in Colorado 
were similar to those in Boston but with one striking 
difference. Adrenocortical steroids were shown to 
reverse rejection in 88% of our dogs, sometimes in 
spectacular fashion, before the steroids almost al-
ways caused fatal peptic erosions of the gastrointesti-
nal tractY 
It was on this dismal record that the clinical 
kidney transplant trials of the early 1960s were 
based. In a display of optimism that would not be 
tolerated in the clinical research climate of today, the 
rare exception was given more weight than the 
customary failure. Thus, the poor results came as no 
surprise when the drugs were first used for patients 
in the same way as had been tried in the dogsK~SIRU 
However, one of the Boston patient s whose transplan-
tation under azathioprine was in April 1962 had 
functional graft survival for more than 18 months 
after receiving the kidney of a patient who could not 
be weaned from a heart-lung apparatus after open 
heart surgery.58,59 Because cardiopulmonary bypass 
was in effect, the physiologic conditions for procure-
ment were unusually advantageous and were in fact 
comparable to those with a "heart beatingcadaver".lio 
At 12 months, the blood urea nitrogen in this patient 
was 100 mg%. The allograft failed between 18 and 24 
months, and thc patient died at 27 months. However, 
this pioneer recipient was the first to achieve long 
survival with azathioprine, and thus he was an 
opening wedge into a new era. 
In Colorado, where the synergism of azathioprine 
and prednisone was known from the animal work, 
these two drugs were used together from the outset 
with results that exceeded everyone's expect a-
tionslil ,1i2 and precipitated a revolution in clinical 
transplantation. Success hinged on the fact that 
acute rejection usually could be reversed with predni-
sone as had been shown in our dogs under baseline 
therapy with azathioprine57 and as Goodwin had 
observed in a kidney recipient whose primary treat-
ment had been with methotrexate and cyclophospha-
mide.44 Both Hamburger l4 and KuSS l3 had adminis-
tered steroids to their irradiated patients although 
no details were given. In a lapse of scholarship in our 
1963 article,') 1 we failed to acknowledge the French 
use of steroids or the earlier experimental work of 
Billingham et a]l9 and the American, Morgan.2o 
Although these oversights were corrected in our 
experimental report,57 we already had unwittingly 
distorted all subsequent literature on this subject. 
The second and far more fundamental observa-
tion in these patients was that the amount of drug 
treatment required to prevent rejection often be-
came less in time,61 allmving the lifetime rehabilita-
tion of some of the patients. Of the first 64 patients 
in the Colorado series compiled between 1962 and 
\larch 1964,62 15 survived for the next 25 years. Two 
stopped all immunosuppression I~thout rejection for 
25 and 27 years, thus mimicking completely the 
phenomenon occasionally observed in dogs and in 
the irradiated Boston and Paris fraternal twins. 0J'ine 
other patients from the era preceding early 1964 
including three treated by David Hume of Richmond 
were still alive in six other centers in the summer of 
1989.40 It was noteworthy that none of these quarter 
century su[y~vors had been given a nonrelated kid-
ney. The first such example in the world was a 
cadaver kidney recipient treated in Paris by Ham-
burger in October 1964 who passed the 25 year mark 
in October 1989.40 
The reversibility of rejection and change in host-
graft relationship eventually were verified with all 
other transplanted organs, beginning with the liver.63 
Although immunosuppression has improved, the 
central therapeutic dogma for solid organ transplan-
tation that had emerged by 196361 ,62 has changed 
French Heritage in Kidney Tramplantation 69 
Table 1. Drug Cocktail Formulation 
Central Therapeutic Dogma 
Baseline therapvwith one 
or two drugs 
Secondary adjustments 
with steroids or anti-
lymphoid agents 
Case-to-case trial (and 
paten tial error) of 
weaning 
Baseline Agents 
Azathioprine 
Cyclophosphamide 
Cyclosporine 
Cyclosporine-azathioprine 
FK506 
FK506-azathioprine 
very little in nt'arly 30 years. The dogma calls for 
daily treatment with one or two baseline drugs with 
further immune modulation by the highly dose-
maneuverable adrenal cortical steroids to whatever 
level is required to maintain stable graft function 
(Table I). The strategy readily incorporated the 
antilymphoid drugs in 1966,54 and after CaIne's 
introduction of cyclosporine64 the dogma again was 
found applicable.65 
A truly amazing period in the history of transplan-
tation was 1959 through 1963, which led to successes 
that exceeded the wildest expectations of the immu-
nologists. At the outset, the Peter Bent Brigham 
Hospital was the sole American forerunner of the 
new field of transplantation, soon to be joined by Will 
Goodwin's University of California at Los Angeles 
program in 1960. By .January 1963, Goodwin's pro-
gram had self-imposed a moratorium, but the num-
ber of active clinical centers in America had grown to 
three-the Brigham, the Medical College of Vir-
ginia, and the University of Colorado. There were 
scarcely more in all of Europe, but by this time the 
two in Paris already had been in existence for more 
than a dozen years. At the end of 1963, the gold rush 
was on with a wild proliferation of kidney transplant 
centers on both sides of the Atlantic. Trials with the 
liver, the next \ital organ beyond the kidney, had 
started66 and clinical heterotransplantation with 
chimpanzee67 and baboon68 donors had been system-
atically tried with encouraging although ultimately 
unsatisfactory results. 
These events and subsequent ones could not have 
transpired in the way they did without the French 
Figure 1. (Left) Rene Kuss (1913- ), approximately 1966. (Right) Jean Hamburger (1909-1992), approximately 1985. 
70 ThomaJ E. Star;:.i 
pioneers, Hamburger the physician and Kuss the 
surgeon (Fig 1), and their friends in Boston whose 
vision was greater than that giwn to most men and 
women. Workers in the two cities founded a clinical 
discipline where none existed before and then per-
sisted despite allegations of folly or worse. The 
French successes with kidney transplantation oyer 
the three-year period from 1959 through early 1962 
kept the flames alive when all other efforts were 
failing. 
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